NeOnc Technologies Holdings, Inc. announced on July 15, 2026, that it has received written feedback from the U.S. Food and Drug Administration (FDA) regarding the chemistry, manufacturing, and controls development program for NEO212, its novel temozolomide-perillyl alcohol conjugate. The company is a biotechnology company focused on developing novel oncology-related therapeutics.
